US-based Thermo Fisher Scientific Inc. has announced the global launch of the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated, functionally closed solution designed to streamline formulation and filling in cell therapy manufacturing.
Because cell therapies often begin with patient-derived cells, manufacturing workflows must accommodate variability in cell count, concentration and viability. As more therapies move toward commercialization, manufacturers are seeking to reduce manual intervention and improve operational efficiency while maintaining strict requirements for sterility, dose accuracy and product consistency.
Formulation and filling have been traditionally performed using manual methods that require careful handling of fragile cells in small volumes, introducing variability and risk of contamination. The CTS Compleo system offers a compact, automated, functionally closed solution for formulation and filling, helping reduce manual intervention and supporting consistent batch-to-batch performance.
Early collaborators are already seeing the benefits from using the advanced technology in the CTS Compleo system to reduce variability and streamline cell therapy manufacturing.
The CTS Compleo system is part of the growing Gibco™ Cell Therapy Systems™ (CTS™) portfolio designed to support cell therapy manufacturers with instruments, consumables and software, GMP-manufactured media and reagents, and viral vector systems.
